Search Results

You are looking at 1 - 10 of 967 items for :

  • Refine by Access: All x
Clear All
Full access

Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff

P atients with breast cancer who are at relatively low risk for recurrence or mortality after local therapy (surgery with or without radiation) face a “grey zone” decision about whether to undergo adjuvant therapy. 1 The choice of therapy

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

NCCN Adjuvant Therapy for Breast Cancer Task Force Members *Robert W. Carlson, MD / Chair#†  ¶¶ Stanford Hospital and Clinics Donald A. Berry, PhD††  The University of Texas M. D. Anderson Cancer Center *Elizabeth Brown, MD  National Comprehensive

Full access

Jennifer A. Ligibel

prognosis in women with early-stage breast cancer. Exercise Intervention Studies in Breast Cancer Survivors Dozens of small-to-moderate–sized interventional studies have tested the feasibility and potential benefits of exercise in the adjuvant

Full access

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta

resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease

Full access

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

Guidelines in Oncology: Prostate Cancer states “new evidence supports offering adjuvant/salvage RT in all men with adverse pathologic features or detectable PSA” 3 (to view the most recent version of these guidelines, visit the NCCN Web site at www

Full access

Katherine Van Loon and Alan P. Venook

Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research

Full access

Maxwell T. Vergo and Al B. Benson III

compared with those with stage II (T4b–a,N0), with 5-year survivals of 83% to 91% versus 58% to 79%, respectively, 5 and yet are offered adjuvant chemotherapy. Evidence shows that stage II and III disease have very similar gene expression profiles and

Full access

Anthony J. Olszanski

Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair

Full access

Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses

receiving adjuvant CRT demonstrated significantly improved median disease-free survival (DFS; 30 vs 19 months; P <.001) and overall survival (OS; 36 vs 27 months; P =.005) compared with those undergoing surgery alone. 4 This survival benefit persisted on

Full access

Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl

its inherent resistance to platinum-based chemotherapy. 4 – 6 In contrast, stage IA, IB, or IC disease solely caused by capsular rupture has been found to confer excellent prognosis, and therefore the benefit of adjuvant therapy is questionable. 1 , 6